Explore
For Enterprise
Join for Free
Log In

艺术与人文
商务
计算机科学
数据科学
信息技术
健康
数学和逻辑
个人发展
物理科学与工程
社会科学
语言学习
学位
证书

浏览 Coursera 的全部课程

浏览
搜索
企业版
登录
免费加入

A Family Member With Colon Cancer

Loading...

个性化医疗案例研究

范德堡大学

4.8（190 个评分） | 15K 名学生已注册

Learn how advances in biomedicine hold the potential to revolutionize drug development, drug treatments, and disease prevention: where are we now, and what does the future hold? This course will present short primers in genetics and mechanisms underlying variability in drug responses. A series of case studies will be used to illustrate principles of how genetics are being brought to bear on refining diagnoses and on personalizing treatment in rare and common diseases. The ethical and operational issues around how to implement large scale genomic sequencing in clinical practice will be addressed. After completing this course, learners will understand 1. The ways in which genetic variants can contribute to human disease susceptibility 2. How to choose among drug therapies based on genetic factors 3. That the functional consequences of the vast majority of genetic variants discovered by modern sequencing are unknown. This course is targeted primarily at physicians 5+ years out of training. Other healthcare providers, medical/health sciences students, and members of the public may also be interested. Course launches January 15, 2016. * The information presented in “Case Studies in Personalized Medicine” is offered for educational and informational purposes only, and should not be construed as personal medical advice. If you have questions or concerns about a medical matter, please consult your doctor or other professional healthcare provider.

查看授课大纲

审阅

4.8（190 个评分）

5 stars
159 ratings
4 stars
25 ratings
3 stars
6 ratings

MT

Apr 24, 2017

I learned more about pharmacogenomics and its application, which is crucial for my career development as a young graduate in biology who is pursuing health sciences.

CZ

Nov 13, 2016

Thank you! I think I'm going to review/re-take this course at least one more time as the lectures are really interesting and insightful.

从本节课中

UNIT 4: CASE STUDIES IN PERSONALIZED MEDICINE, PART 2

Module 7 continues our focus on case studies with a look at some cases that illustrate how personalized medicine informs treatment decisions related to specific diseases/conditions. These include cystic fibrosis, Marfan syndrome, heart failure, neuropsychiatric diseases, and diabetes. Three cases/lessons focus specifically on how genomic medicine informs testing for and treatment of cancer.

Cystic Fibrosis11:45

Marfan Syndrome11:35

A Case of Idiopathic Heart Failure16:02

Personalizing Care in Neuropsychiatric Disease18:53

Personalizing Care in Diabetes21:52

Genomics to Subtype Cancer11:34

A Family Member With Breast Cancer14:35

A Family Member With Colon Cancer11:31

**Inside VUMC: Organizing Infrastructure to Support Genetic Testing Decisions1:12

教学方

Dan Roden, M.D.
Professor of Medicine and Pharmacology

脚本

[MUSIC]

Today I'm going to continue the theme of family cancer susceptibility and

we're going to start with a case of a woman who comes to you,

she's 25 years old and she says, my father died of colon cancer when he was 47.

Do I need to be worried?

So the first thing that we do in a situation like this is we

ask the details of the father's history, the mother's history, and go back through

the rest of the family and ask if there's any other cancer or any other diseases.

And when we do that in this particular In case we find that an aunt has uterine

cancer and then the father's father also had colon cancer.

So this is a family that you'd have to worry that there's something going on

here that would make them susceptible to colon cancer.

Colon cancer, just to review,

is the second leading cause of cancer death in the United States.

These are separated on this particular slide by mortality in men and women.

Lung cancer, unfortunately, is by far, the leader.

And then in men, prostate and in women, breast cancer comes in second, but

colorectal comes in third for both and so across the United States, colorectal

cancer is the second leading cause of cancer deaths in men and in women.

Colon cancer, like breast cancer often has a family history component and

you can separate that into people who have real genetic syndromes five to 10%

of patients who will have a history like the one I just showed you.

And then another group of patients who have a very strong family history,

a suggestive family history, in whom we don't find a gene.

And then the sporadic cases in green where

we wonder if there could be a genetic risk factor.

But there's not anything in the family that suggests that there is.

The major syndromes that predispose to colon cancer, Lynch syndrome,

which I'm going to talk a little bit about,

the Familial adenomatuous polyposis syndrome, FAP, is also mentioned and

then there's something called Gardner syndrome is a variant of FAP.

Lynch syndrome, describe in 1966 by Lynch Two to 3% of all colorectal cancers.

Typically in the right colon,

the ascending colon, sometimes with multiple primaries, polyps can be present.

It's an autosomal dominant disease.

The lifetime risk of cancer is 80% so this is highly penetrate.

It doesn't mean that you going to get colon cancer when you're 25, but

if you live to be 90 you will have a high, high likelihood of getting colon cancer.

There is an association with many other forms of cancer,

including endometrial cancer As in this particular patient, gastric cancer or

ovarian cancer and other GI tract cancers, and a smattering of other cancers as well.

Lynch syndrome is now understood to be a disease of defective DNA mismatch repair,

so there's this idea that cells, when they replicate, sometimes don't get the DNA

exactly replicated right but they have mechanisms to fix that.

In the case, in this case here, for example, the replication

of the T Strand should result in an A but occasionally results in a G.

So the body has mechanisms to correct that G back to an A and

not let that mutation accumulate over time.

And one of the genes that's involved in that is shown

here on the bottom in a crystal structure and it's MSH6,

which is the most commonly mutated gene in Lynch syndrome.

So, the problem in Lynch syndrome is a problem of defective DNA mismatch repair.

There are many other genes involved, but 90% of the mutations are caused by,

90% of the cases are caused by mutations in MSH6 or M MLH1.

The pathological characteristic is microsatellite instability which is

something that can be detected by the pathologist using DNA sequence analysis.

And the diagnosis is either by germline genetic testing to find a mutation in

MSH6, MLH1, or other Lynch syndrome associated genes, or

by analysis of the tumor itself, to detect these mutations and

the microsatellite instability.

So faced with a patient like the one that I presented to you, the question is,

should they have genetic testing for Lynch syndrome or not?

And there are criteria that have been set out to

identify patients who have a high likelihood of having a positive test.

And those criteria are the so called Amsterdam II criteria.

There are other criteria that have been described and there are so

called the 321 criteria.

So at least three relatives with colorectal or

other Lynch syndrome associated cancers, this patient has that.

At least two successive generations, this patient has that.

And at least one relative diagnosed before age 50, this patient has that as well.

You need to eliminate the diagnosis of Familial adenomatous polyposis, and

it would be desirable to have the tumors verified by pathology.

So faced with a patient like this, it's no different from a patient with

a cardiomyopathy risk or an arrhythmia risk or breast cancer risk.

The best person in whom to do the genetic testing is the person who has the cancer

and in whom we can make or not make the diagnosis of Lynch Syndrome.

And then we can ask the question is the relative at risk or not because we could

say does the relative have the mutation that the patient who has the disease has.

In this particular case, we don't have that luxury

because the patient the closest relative has died of colon cancer.

And that is often the case.

We're faced with testing people in whom there's no cancer yet

and in whom if we find a mutation we're never sure whether that mutation

might be a benign fellow traveler or might be a causative mutation.

So again, this is the problem that we face in a family like this.

So the management in this particular case is genetic testing

in the affected individual, if possible.

If not, then this particular young

woman should get genetic testing based on the Amsterdam II criteria.

And if they have a mutation that is known to be pathogenic

in one of those two Lynch syndrome genes or others.

Then you can diagnose them as having increased cancer susceptibility.

So if the genetic testing is positive, then colonoscopy every year or

two starting at a very young age.

The age is either 20 to 25 something like that or

ten years earlier than the earliest case of colon cancer in the family.

So the earliest case of colon cancer in this family was 47 so this person would

start colonoscopies at age 37 or 25 whichever is younger, so age 20 or 25.

And because this person is a woman and there's a risk of uterine cancer as well,

gynecological exams, including the potential for trans-vaginal ultrasounds or

testing of cancer markers that are circulating in the blood stream, Ca125,

starting again at a relatively young age to detect early, and to treat early.

The other disease that is much rarer but

has an exuberant clinical phenotype is familial adenomatous polyposis.

Very rare.

Autosomal dominant, so a single gene mutation will cause this.

And the mutation is in a gene called APC, which is a tumor suppressor gene.

So again, you have a mutation in a tumor suppressor gene that

wipes out its function.

And all you need is a mutation in the other form of the tumor suppressor gene

and suddenly you have no tumor suppression capability.

The pathological or the clinical hallmark of this disease is carpeting,

literally carpeting of the colonic mucosa by polyps.

Very, very high likelihood of colon cancer by age 50 with

other cancers that are listed here, stomach cancer, small bowel cancer,

pancreas, thyroid, and hepatoblastoma in children.

So that has implications for screening for cancers along the way.

So the management of a person who's an FAP mutation carrier is sigmoidoscopy

starting off at a very young age and

once polyp polyps are detected, probably a prophylactic colectomy and

you still have to pay attention to the ileal pouch and to the rectal remnant.

To make sure that

they're not developing polyps in those areas and have a cancer risk as well.

Because of the risk of stomach and small bowel malignancies, upper GI endoscopy

starting at age 25 and then every so often after that and in infants and

in children screening for hepatoblastoma up until age five with ultrasound.

On an alpha-fetoprotein measurements in the endoplasma.

So I've gone over now two cases of breast cancer

susceptibility in the previous module and colon cancer susceptibility here.

And the problem is one, identifying

patients who need to have referrals to specialized cancer genetic clinics.

So that's the small five to10% slice.

Perhaps the pink slice as well, the strong family history slice,

although there's a chunk of those in whom we don't find mutations at this point.

The big public health problem, of course, is the green part.

And again colon cancer is one of the leading causes mortality so

we've been focused on personalizing medicine but

there's also an aspect to this that is preventive medicine and

what do you do about preventing colon cancer a leading cause of death leading

preventable cause of death In the United States.

So there are guidelines from the Canadian Cancer Society

that are difficult to read on this slide, but lay out for

you what you should do in terms of screening people for

genetic risk, high risk, medium risk, and low risk.

But the most interesting category of all are the people who are at population risk.

Because its the people who are at population risk who make up the vast

majority of death from colon cancer.

It it says meets know the criteria for genetic testing but

still have Has a one in 16 lifetime chance of developing colorectal cancer.

So the recommendations for genetic screening are interesting and

part of personalizing medicine, but we shouldn't loose sight of the fact that

this is a really highly prevalent disease and if managed correctly entirely or

largely preventable at least in terms of deaths.

And the way it's prevented is by annual stool fecal occult blood and

regular examinations of the colon by x-rays or

by colonoscopies starting at age 50,

and that's the recommendation in the bottom green set of panels.

So personalizing medicine is important.

It's important to pick out people in whom special different kinds of approaches need

to be used.

But we shouldn't lose sight of that fact that this is

a largely preventable disease if appropriate prophylaxis is put in place.

So I think there are two bottom line messages here.

[APPLAUSE]

探索我们的目录

免费加入并获得个性化推荐、更新和优惠。

Coursera 致力于普及全世界最好的教育，它与全球一流大学和机构合作提供在线课程。

© 2019 Coursera Inc. 保留所有权利。

通过 App Store 下载

通过 Google Play 获取

Coursera
关于
管理团队
工作机会
目录
证书
MasterTrack™ 证书
学位
企业版
政府版

社区
Learners
Partners
Developers
Beta Testers
Translators

连接
博客
Facebook
领英
Twitter
Instagram
YouTube
技术博客

更多
条款
隐私
帮助
内容访问
媒体
联系我们
目录
附属公司